An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. - Concepedia

Concepedia

Publication | Closed Access

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

40

Citations

0

References

2011

Year

G. D. Demetri, Michael C. Heinrich, Bartosz Chmielowski, J. A. Morgan, Shaji George, Rosie Bradley, Ronald K. Blackman, Florentina Teofilovici, J. Fletcher, William D. Tap,

Journal of Clinical Oncology

Clinical TranslationMedicineHsp90 Inhibitor GanetespibClinical TrialsPathologyPharmacotherapyOncologyRadiation OncologyHealth Sciences

Abstract

10011